Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 187-194

  De Jonge, Maja J A ^a   Sparreboom, Alex ^a   Planting, André S T ^a   Van Der Burg, Maria E L ^a   De Boer Dennert, Maureen M ^a   Steeg, Judith Ter ^a   Jacques, Christian ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; FATIGUE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033989206     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.187     Document Type: Article

References (44)

1. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
2. Eng W-K, Faucette L, Johnson RK, et al: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
3. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
4. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995
5. Boothman DA, Trask DK, Pardee AB: Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-Lapachone, an activator of topoisomerase I. Cancer Res 49:605-612, 1989
6. Rumbos H, Grosovsky A: Regulation of topoisomerase I activity following DNA damage: Evidence for a topoisomerase I complex. Proc Am Assoc Cancer Res 38:181, 1997 (abstr 1214)
7. Fukuda M, Nishio K, Kanzawa F, et al: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56:789-793, 1996
8. Aoe K, Kiura K, Ueoka H, et al: Down-regulation of topoisomerase I induced by cisplatin. Proc Am Assoc Cancer Res 38:15, 1997 (abstr 99)
9. Takiyama I, Terashima M, Ikeda K, et al: Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines. Proc Am Assoc Cancer Res 38:15, 1997 (abstr 101)
10. Ma J, Maliepaard M, Nooter K, et al: Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307-316, 1998
11. Maliepaard M, van Klink Y, Root BJG, et al: Schedule-dependent cytotoxicity of topotecan or SN-38 and platinum (H) and (IV) compounds in vitro. Proc 8th Conf DNA Topoisomerase 1997 (abstr 92)
12. Kano Y, Suzuki K, Akutsu M, et al: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610, 1992
13. Keane T, McGuire W, Petros J, et al: CPT-11/cisplatin: An effective preclinical combination in the therapy of advanced human bladder cancer (TCC). Proc Am Soc Clin Oncol 14:491, 1995 (abstr 1605)
14. Katz EJ, Vick JS, Kling KM. et al: Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 26:724-727, 1990
15. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992
16. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993
17. Sugiyama T, Takeuchi S, Noda K, et al: Phase I study of irinotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma. Proc Am Soc Clin Oncol 13:268, 1994 (abstr 856)
18. Kobayashi K, Shinbara A, Kamimura M, et al: Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small cell lung cancer. Cancer Chemother Pharmacol 42:53-58, 1998
19. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997
20. Ueoka H, Tabata M, Kiuraa K, et al: Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study. Br J Cancer 79:984-990, 1998
21. Mori K, Ohnishi T, Yokoyama K, et al: A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 39:327-332, 1997
22. Saltz LB, Spriggs D, Schaaf LJ, et al: Phase I clinical and pharmacologie study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16:3858-3865, 1998
23. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12:90-96, 1994
24. Mori K, Hirose T, Machida S, et al: A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 33:503-505, 1997
25. Mori K, Hirose T, Tominaga K: Phase II study irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 16:476a, 1997 (abstr 1714)
26. DeVore R, Crawford J, Dimery I., et al: Phase II trial of irinotecan (CPT-11) plus cispiatin (CDDP) in advanced NSCLC. Proc Am Soc Clin Oncol 16:466a, 1997 (abstr 1674)
27. Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16:1068-1074, 1998
28. Shirao K, Kondo H, Saito D, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997
29. Sugiyama T, Yakushiji M, Nishida T, et al: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128:211-218, 1998
30. Sugiyama T, Noda K, Yakushiji M: Multicentric phase II trial of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in recurrent or advanced cervical cancer: Japan CPT-11 study group trial. Proc Am Soc Clin Oncol 17:352a, 1998 (abstr 1360)
31. De Bruijn P, Verweij J, Loos WJ, et al: Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr 698:277-285, 1997
32. Sparreboom A, De Bruijn P, De Jonge MJA, et al: Liquid Chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B 712:225-235, 1998
33. Reed E, Sauerhoff S, Poirier MC: Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: A novel use of graphite furnace spectrometry. Atom Spectr 9:93-95, 1988
34. Ma J, Verweij J, Planting AST, et al: Current sample handling methods for measurement of platinum-DNA-adducts in leukocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair. Br J Cancer 71:512-517, 1995
35. Ma J, Stoter G, Verweij J, et al: Comparison of ethanol plasma protein precipitation with plasma ultranltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentration. Cancer Chemother Pharmacol 38:391-394, 1996
36. Sparreboom A, de Jonge MJA, De Bruijn P, et al: Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747-2754, 1998
37. Schellens JHM, Ma J, Planting AST, et al: Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569-1575, 1996
38. de Jonge MJA, Verweij J, de Bruijn P, et al: Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 18:195-203, 2000
39. Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996
40. Cunningham D, Pyrhönen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
41. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
42. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
43. Rivory LP, Haaz MC, Canal P, et al: Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266, 1997
44. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695, 1996